In November, clinical trial platform developer Medable raised $91 million in private funding, amid the COVID-19 pandemic that touched off huge demand among pharmaceutical companies looking to initiate “siteless” or virtual clinical trials. In May of this year, Science 37, received $200 million in PIPE funding, announced a merger, and its plans to be a major public listing on Nasdaq in 2021. Provider of the one of the industry’s first Decentralized Clinical Trial Operating System, the company has penned deals with the likes of Medgate, Signant Health and Duke Clinical Research Institute to offer virtual trials.
Those are just a few examples of companies stepping up to facilitate decentralized clinical trials. These trials can offer several advantages for pharmaceutical companies, including the ability to recruit patients who can’t travel to physical sites to participate in research, become more cost-efficient and enable the enhanced use of telehealth in clinical trials.
We’ll explore the role of CROs in siteless trials and the opportunities and challenges for CROs to expand their capabilities in this burgeoning area.
- Best practices for choosing and providing user-friendly equipment that patients in clinical trials will need to participate in virtual trials.
- Overcoming operational challenges that can arise when patients participate in virtual trials, for example by using hybrid models that incorporate in-home visits from nurses and other clinicians.
- How to work with participants to ensure the security of data that’s transferred from wearables and other equipment used in their homes to clinical trial investigators.